← Back to Screener
Protagonist Therapeutics, Inc (PTGX)
Price$105.47
Favorite Metrics
Price vs S&P 500 (26W)13.07%
Price vs S&P 500 (4W)-2.30%
Market Capitalization$6.73B
P/E Ratio (Annual)21.85x
All Metrics
P/CF (Annual)116.69x
Book Value / Share (Quarterly)$9.82
P/TBV (Annual)4.61x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)20.07%
Cash Flow / Share (Quarterly)$0.90
Price vs S&P 500 (YTD)17.20%
Net Profit Margin (TTM)-282.83%
EPS (TTM)$-2.04
10-Day Avg Trading Volume0.75M
EPS Excl Extra (TTM)$-2.04
Revenue Growth (5Y)9.96%
EPS (Annual)$-2.05
ROI (Annual)-21.17%
Net Profit Margin (5Y Avg)-257.85%
Cash / Share (Quarterly)$9.07
P/E Basic Excl Extra (TTM)130.98x
Revenue Growth QoQ (YoY)-95.64%
P/E Normalized (Annual)21.85x
ROA (Last FY)-19.48%
Revenue Growth TTM (YoY)-89.41%
EBITD / Share (TTM)$-2.47
ROE (5Y Avg)-20.96%
Operating Margin (TTM)-343.63%
Cash Flow / Share (Annual)$0.90
P/B Ratio10.95x
P/B Ratio (Quarterly)8.88x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)143.46x
Net Interest Coverage (TTM)-7.30x
ROA (TTM)-18.40%
EV / EBITDA (TTM)320.00x
EPS Incl Extra (Annual)$-2.05
Current Ratio (Annual)12.71x
Quick Ratio (Quarterly)12.58x
3-Month Avg Trading Volume0.83M
52-Week Price Return131.40%
EV / Free Cash Flow (Annual)117.71x
P/E Incl Extra (TTM)130.98x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.24
P/S Ratio (Annual)146.25x
Asset Turnover (Annual)0.07x
52-Week High$107.84
Operating Margin (5Y Avg)-279.15%
EPS Excl Extra (Annual)$-2.05
CapEx CAGR (5Y)27.60%
Tangible BV CAGR (5Y)12.32%
26-Week Price Return21.82%
Quick Ratio (Annual)12.58x
13-Week Price Return24.35%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.71x
Enterprise Value$6,601.515
Revenue / Share Growth (5Y)-2.75%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)8.95%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-281.01%
Cash / Share (Annual)$9.07
3-Month Return Std Dev41.86%
Net Income / Employee (TTM)$-1
ROE (Last FY)-21.17%
Net Interest Coverage (Annual)-376.80x
EPS Basic Excl Extra (Annual)$-2.05
P/FCF (TTM)17.11x
Receivables Turnover (TTM)12.10x
EV / Free Cash Flow (TTM)117.71x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.04
Receivables Turnover (Annual)9.87x
ROI (TTM)-19.89%
P/S Ratio (TTM)146.25x
Pretax Margin (5Y Avg)-257.29%
Revenue / Share (Annual)$0.72
Tangible BV / Share (Annual)$4.37
Forward P/E32.65x
Price vs S&P 500 (52W)96.30%
P/E Ratio (TTM)130.98x
EPS Growth TTM (YoY)-76.41%
Year-to-Date Return21.34%
5-Day Price Return8.62%
EPS Normalized (Annual)$-2.05
ROA (5Y Avg)-18.42%
Net Profit Margin (Annual)-282.83%
Month-to-Date Return0.55%
Cash Flow / Share (TTM)$-2.59
EBITD / Share (Annual)$-2.47
Operating Margin (Annual)-343.63%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)116.69x
ROI (5Y Avg)-20.96%
P/E Excl Extra (TTM)130.98x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.04
P/TBV (Quarterly)3.29x
P/B Ratio (Annual)8.88x
Pretax Margin (TTM)-281.01%
Book Value / Share (Annual)$9.82
Price vs S&P 500 (13W)21.48%
Beta1.97x
P/FCF (Annual)120.00x
Revenue / Share (TTM)$0.72
ROE (TTM)-19.89%
52-Week Low$41.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.21
4.21
4.21
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PTGXProtagonist Therapeutics, Inc | 146.25x | -89.41% | — | — | $105.47 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Protagonist Therapeutics is a biopharmaceutical company developing peptide-based therapeutics across inflammation, hematology, and metabolic diseases using a proprietary platform. Its clinical pipeline includes rusfertide for polycythemia vera and icotrokinra for inflammatory conditions, complemented by preclinical programs in obesity and iron metabolism. The company advances its candidates through internal research and strategic collaborations.